J&J innovation team sets up international collaboration to discover Alzheimer’s drugs

John Carroll J&J has spent hundreds of millions of dollars in a so-far failed effort to develop a late-stage biologic that could be used to treat Alzheimer's. And it's now ...

EU watchdogs demand info on AstraZeneca’s disputed Brilinta trial

Tracy Staton Last week, AstraZeneca succinctly disclosed that Department of Justice investigators are digging into its data on the blood thinner Brilinta. Now, European regulators are ...

CereSpir Secures CHF 5074 Rights

mia.burns CERESPIR INCORPORATED SECURES EXCLUSIVE WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION RIGHTS FOR CHF 5074 FROM CHIESI FARMACEUTICI S.p.A. November 8, 2013 – New York, NY, ...

Teva fills CFO position as Desheh steps up to CEO

Alok Saboo FierceBiotech News

FDA staffers throw cold water on Sanofi’s Lemtrada hopes

Tracy Staton If you're a drug developer, which 6 words do you never, ever want to see in an FDA review of a potential new product? The 6 words applied to Sanofi's multiple sclerosis ...

Keryx Updates on Ongoing Zerenex Study

mia.burns Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia ...

UPDATED: FDA casts ‘fatal’ doubts on Sanofi’s long-stalled MS drug Lemtrada

Damian Garde Sanofi's multiple sclerosis drug Lemtrada may be too dangerous to warrant FDA approval, agency staff said, potentially damning news for an injection that has slogged ...

Eisai bets another $60M on Arena’s Belviq with worldwide marketing deal

Tracy Staton Eisai gave Arena Pharmaceuticals' obesity drug Belviq another vote of confidence. The Japanese drugmaker, already marketing the drug in the U.S., signed up to promote ...

Ariad hacks 160 workers in aftermath of Iclusig disaster

Tracy Staton Ariad Pharmaceuticals is letting go of nearly half its U.S. staff just a week after pulling its leukemia drug Iclusig from the market at the FDA's request. FiercePharma ...

NPC Elects Boehringer Executive as Board Chairman

mia.burns Boehringer Ingelheim’s Jeff Huth Elected as National Pharmaceutical Council’s Chairman of the Board   Washington, DC (November 8, 2013)–The National Pharmaceutical ...

GlycoMimetics puts off $64M IPO pitch

Damian Garde After downsizing its sought-after haul, GlycoMimetics is postponing its $ 64 million IPO plans, a sign that the year's investor frenzy over biotech debuts may not ...

Bayer envisions bigger Eylea market with new EU use

Tracy Staton Bayer has taken another step toward fulfilling blockbuster ambitions for its eye drug Eylea. The German drugmaker asked European regulators to approve the vision-loss treatment ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS